Elanco Animal Health INC Form 4 insider transactions

Elanco Animal Health Inc.'s EVP, Manufacturing and Quality, Grace McArdle, reported a planned disposition of 4,346 common shares on July 3, 2025, to cover tax liabilities from restricted stock unit vesting.

Elanco Animal Health Inc. director Kapila K. Anand acquired 603.9916 deferred stock units by electing to defer cash retainer fees, increasing her total beneficial ownership to 8,085.358 units.

Elanco Animal Health Inc. executive Rajeev A. Modi acquired 98.9937 deferred stock units, increasing his beneficial ownership to 6,460.6903 units.

Elanco Animal Health Inc.'s President, CEO, and Director, Jeffrey N. Simmons, is scheduled to acquire 193.7887 deferred stock units on June 27, 2025, increasing his beneficial ownership to 16,849.4516 units.

Rajeev A. Modi, Executive Vice President at Elanco Animal Health Inc., acquired 102.4345 deferred stock units, increasing his direct beneficial ownership in the company.

Elanco Animal Health Inc.'s President, CEO, and Director, Jeffrey N. Simmons, has acquired 200.5243 deferred stock units, increasing his beneficial ownership.

Elanco Animal Health Inc.'s President, CEO, and Director, Jeffrey N. Simmons, acquired 206.0446 deferred stock units on May 30, 2025, increasing his direct beneficial ownership.

Rajeev A. Modi, Executive Vice President at Elanco Animal Health Inc., acquired 105.2545 deferred stock units on May 30, 2025, increasing his beneficial ownership.

Elanco Animal Health's CEO, Jeffrey Simmons, reports the acquisition of deferred stock units convertible to common stock.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units representing the right to receive common stock or cash equivalent.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Elanco Animal Health CEO Jeffrey N. Simmons acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Jeffrey N. Simmons, CEO of Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired deferred stock units convertible to common stock, as reported in a recent SEC filing.

Jeffrey N. Simmons, CEO of Elanco Animal Health, reports acquisition of deferred stock units.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, reported the acquisition of deferred stock units convertible to common stock.

Timothy Bettington, an executive at Elanco Animal Health, reported disposing of 23,558 shares of common stock to cover tax obligations.

Director Kapila K. Anand reports acquisition of deferred stock units in Elanco Animal Health Inc. through a director deferral plan.

Rajeev A. Modi, an Executive Vice President at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent.

Jeffrey N. Simmons, CEO of Elanco Animal Health, reports acquisition of deferred stock units convertible to common stock.

Director Lawrence Erik Kurzius reports purchasing 20,000 shares of Elanco Animal Health Inc. (ELAN) in two transactions on March 7th and March 11th, 2025.

Elanco Animal Health Inc. executive Rajeev A. Modi reports the acquisition of deferred stock units convertible to common stock following termination of employment or during a specified future year.

Elanco Animal Health's CEO, Jeffrey N. Simmons, acquired deferred stock units representing the right to receive common stock or cash equivalent, according to a recent SEC filing.

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, acquired deferred stock units representing the right to receive common stock or cash equivalent.

Director R. David Hoover of Elanco Animal Health Inc. reports the acquisition of 25,000 shares of common stock at a price of $10.9023 per share on March 5, 2025.

Jose Manuel Correia de Simas, an Executive Vice President at Elanco Animal Health, received stock options and restricted stock units, and disposed of common stock according to a recent SEC Form 4 filing.

Todd S. Young, Executive Vice President and CFO of Elanco Animal Health, reports the acquisition of restricted stock units and stock options.

Ellen de Brabander, an Executive Vice President at Elanco Animal Health, reported the grant of restricted stock units and stock options in a recent Form 4 filing.

Timothy J. Bettington, an Executive Vice President at Elanco Animal Health, was granted stock options and restricted stock units on March 3, 2025, according to a Form 4 filing.

Elanco Animal Health's CEO, Jeffrey Simmons, reported the acquisition of restricted stock units and stock options in a recent Form 4 filing with the SEC.